Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663208 · ClinicalTrials.gov registry record · Phase 2
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00663208 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 167 participants.
The verdict
NCT00663208, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C infection
Interventions
- DRUG Placebo
- DRUG Daclatasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663208
The ClinicalTrials.gov registry entry for NCT00663208 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00663208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00663208 about?
NCT00663208 is a clinical study titled "A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects". The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C infection
What is the current status of trial NCT00663208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2008-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00663208?
The interventions under investigation include: Placebo (DRUG), Daclatasvir (DRUG).
Who is sponsoring clinical trial NCT00663208?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.